Spending money for a launch that won’t happen

The WSJ writes about the sad story of Myriad Genetics, who paid $200,000 for a huge coming out party at a conference for their Alzheimer’s drug.

Trouble is, the drug didn’t work, so they’re left with an empty, fancy booth.

Tragically comical.

Similar Posts:

• Are we wasting money on Alzheimer’s care?
• An incredible surgery, but would future surgeons be able to accomplish the same feat?
• Are hospitals who limit ties with drug companies at a competitive disadvantage?